Relay Therapeutics Has Interesting Science That Needs To Be Proven In Trials
Relay Therapeutics faces challenges with limited clinical data and high expenses but shows promise with their 4D drug design ...
pharmaphorum1d
Eisai files biliary tract cancer drug tasurgratinib in Japan
Tasurgratinib (also known as E-7090) is an oral selective FGFR1, FGFR2, and FGFR3 inhibitor that, if approved, will join other drugs in the class on the market, including Incyte’s Pemazyre ...